-
Could rewiring the brain’s “brakes” improve movement in Huntington’s disease?
6 min read
Latest News
-
Turning down mismatch repair genes slows Huntington’s repeat growth in human neurons
9 min read
In a human cellular system, scientists dialed back mismatch repair genes to reduce CAG expansion by up to 69%. This work is in its early days, but it shows promise for “anti-expansion” therapies that could be used to delay HD onset.
-
Huntington’s Disease Therapeutics Conference 2026 – Day 3
28 min read
Day 3 of the HD Therapeutics Conference dives into breakthrough science, new tools and bold ideas that are pushing HD research toward better treatments.
-
Huntington’s Disease Therapeutics Conference 2026 – Day 2
17 min read
HDBuzz is back with Day 2 of the 21st annual CHDI HD Therapeutics Conference in Palm Springs, CA. We heard about new techniques to zoom in on HD biology in extraordinary detail.
-
Huntington’s Disease Therapeutics Conference 2026 – Day 1
32 min read
HDBuzz is at CHDI’s Huntington’s Disease Therapeutics Conference, ready to bring you live updates from the most recent research in the field. Get ready for some exciting science!
-
Australia Opens The Door for SKY-0515: Skyhawk Seeks Provisional Approval for Its Oral HD Drug
7 min read
An oral Huntington’s disease drug is eligible for accelerated approval in Australia. This isn’t full approval yet, but it opens a faster path to potentially getting this once-daily pill to people with HD sooner.
-
The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy
10 min read
The FDA wants more data before approving AMT-130 for Huntington’s disease in the U.S. On March 2026, uniQure shared in an update that current Phase 1/2 data weren’t enough for the agency. A new randomized, sham-controlled trial may be required.
-
Vico’s Trial Adjusts With Twice-Yearly Dosing, And The U.S. Is Next
6 min read
Vico Therapeutics’ Huntington’s disease drug VO659 is now being tested just twice a year, and the FDA has cleared the way for US trials to begin later this year.
-
February 2026: This Month in Huntington’s Disease Research
7 min read
February 2026 HD research recap: published trial data from branaplam trial; new insights into the genetics of the HD “grey zone”; plus worms, brain circuits, eye tracking, and the hidden psychological weight of living at risk.
-
A Window into the Eyes: Using Ocular Biomarkers to Track Progression in Huntington’s Disease
6 min read
A new review from the University of Cambridge explores ocular biomarkers in HD, including retinal scans and eye movement tracking.
-
A Fault In The Supercomputer
8 min read
Your brain is an advanced supercomputer. But in HD, a core processor starts to malfunction. A research group at UCLA has taken a close look to visualize the specific circuits going haywire – and how they look different in HD.
HDBuzz Trial Tracker
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
